Format

Send to

Choose Destination
Cancer Treat Rev. 2011 Jun;37(4):266-83. doi: 10.1016/j.ctrv.2010.08.008. Epub 2010 Sep 21.

Treatment of relapsed and refractory multiple myeloma in the era of novel agents.

Author information

1
Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands. n.w.c.j.vandedonk@umcutrecht.n

Abstract

The introduction of the Immunomodulatory drugs (IMiDs) and proteasome inhibitors, used either as a single-agent or combined with classic anti-myeloma therapies, has improved the outcome for patients with relapsed myeloma. However, there is currently no generally accepted standard treatment for relapsed/refractory myeloma patients, partly because of the absence of trials comparing the efficacy of the novel agents in relapsed/refractory myeloma. Choice of a new treatment regimen depends on both patient and disease-specific characteristics. A lenalidomide-based regimen is the first choice in patients with neuropathy, while bortezomib has the highest efficacy in patients with renal insufficiency and is not associated with increased risk of thromboembolism. A second autologous stem cell transplantation (auto-SCT) can be applied in patients with a progression-free period of ≥ 18-24 months after the first auto-SCT. In high-risk relapse such as occurring early after auto-SCT consolidation with allogeneic SCT can be considered. In this review we provide an overview of the various salvage regimens and give recommendations for treatment of patients with relapsed/refractory myeloma in different clinical settings.

PMID:
20863623
DOI:
10.1016/j.ctrv.2010.08.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center